Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $414.00 | Underweight | Wells Fargo |
| 9/26/2025 | $569.00 | Outperform | RBC Capital Mkts |
| 6/2/2025 | $405.00 | Overweight | Cantor Fitzgerald |
| 4/25/2025 | Overweight → Equal Weight | Wells Fargo | |
| 4/21/2025 | $314.00 | Underperform → Neutral | BofA Securities |
| 7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley |
| 2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman |
| 2/5/2024 | $330.00 | Outperform | Leerink Partners |
Wells Fargo initiated coverage of United Therapeutics with a rating of Underweight and set a new price target of $414.00
RBC Capital Mkts initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $569.00
Cantor Fitzgerald initiated coverage of United Therapeutics with a rating of Overweight and set a new price target of $405.00
144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)
144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)
144 - UNITED THERAPEUTICS Corp (0001082554) (Subject)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision an
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding Pulmonary Hypertension: Exploring Best Practices in PH-ILD Detection and Management dinner symposium and the Women in Chest Medicine Annual Luncheon. "CHEST is a powerful platform for United Therapeutics and the pulmonary hypertension community to connect, share new developments, and elevate patient care," said Andrew Nelsen, PharmD, VP of Global Medi
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time. During the webcast, Steven D. Nathan, M.D., Schar Chair, Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and Chair of the TETON Steering Committee, will review data that were presented earlier in the day at the European Respiratory Society Congress. He will be joined by Leigh Peterson, Ph.D., Executive Vice President, Product De
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, October 29, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision an
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, July 30, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics, our vision and mis
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. "2025 is off to a tremendous start as we reported yet another quarter of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we'll progress our innovation and revolution waves of growth with the readout
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)